Area of research
Cardiology and Cardiovascular Medicine · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Cardiomyopathy and Myosin Studies, Cardiovascular Function and Risk Factors, Prenatal Screening and Diagnostics, and Cardiovascular Effects of Exercise.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
Response to Mavacamten in Patients With High Baseline Left Ventricular Filling Pressures in the EXPLORER-HCM Trial.
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.
Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument.
Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial.
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States